Caladrius Biosciences Treats First Patient in the Phase IIb FREEDOM Trial of CLBS16 for the Treatment of Coronary Microvascular Dysfunction

Caladrius Biosciences, Inc. announced that it has treated the first patient in its Phase IIb FREEDOM trial of CLBS16 as a therapy for coronary microvascular dysfunction at The Christ Hospital Health Network in Cincinnati, Ohio.